AbelZeta Pharma

Clinical Trials

Currently we are performing clinical investigations of novel CAR-T and TIL therapies in multiple disease areas including hematological malignancies, solid tumors and inflammatory and immunological diseases.

Product Indication Clinical Study NCT NUMBER(s) PUBLICATION/PRESENTATION
C-CAR039 r/r B-NHL Investigator-initiated trial in China NCT04317885

ASCO 2021 Abstract

ASCO 2021 Presentation

ASH 2023 Paper

ASH 2023 Presentation

NCT04655677
NCT04696432
NCT04693676
Phase 1b/2 trial in China NCT05800977  
Phase 1b trial worldwide (ex-Greater China) licensed to JNJ NCT05421663

 

C-CAR066 r/r B-NHL including prior CAR-T Investigator-initiated trial in China NCT04036019

ASCO 2021 Abstract

ASCO 2021 Presentation

ASH 2023 Paper

ASH 2023 Poster

Phase 1b trial worldwide (ex-Greater China) licensed to JNJ NCT05784441

 

C-CAR088 r/r Multiple Myeloma Phase 1b/2 trial in China NCT05521802  
Investigator-initiated trial in China NCT04322292 Journal for Immunotherapy of Cancer 09/2022
NCT03815383
NCT03751293
NCT04295018
C-CAR031 Hepatocellular Carcinoma (HCC) Investigator-initiated trial in China NCT05155189

AACR Abstract 04/2023

AACR Poster 04/2023

C-TIL051 Non Small Cell Lung Cancer (NSCLC) Phase 1 trial US NCT05676749  
Scroll to Top